# Er:YAG Laser Therapy for Xanthelasma Palpebrarum: A Retrospective Case Series Evaluating Clinical Efficacy, Safety, and Patient Outcomes in Periocular Lesion Management

**Authors:** Saman Al-Zahawi, Sara Masoomi, Ifa Etesami

PMC · DOI: 10.1155/crdm/4616721 · 2025-06-09

## TL;DR

This study shows that Er:YAG laser therapy is effective and safe for treating eyelid lesions called xanthelasma, with quick recovery and no side effects.

## Contribution

The study demonstrates the efficacy and safety of Er:YAG laser for xanthelasma treatment with no recurrence or complications.

## Key findings

- Three Er:YAG laser sessions effectively reduced xanthelasma lesions with patient satisfaction.
- No recurrence or side effects were observed in 12 months post-treatment.
- Er:YAG laser showed faster recovery and fewer complications compared to other laser types.

## Abstract

Xanthelasma palpebrarum (XP) is a benign condition of the eyelid skin, characterized by the appearance of well-defined, bilateral, yellow-colored papules or plaques in the periorbital area. Although patients often seek dermatological consultation for cosmetic reasons, the associated medical implications, especially in younger individuals, hold significant medical importance. XP can be treated through various methods such as surgical removal, trichloroacetic acid (TCA) 70% application, cryotherapy, and laser procedures. Among the laser therapies (CO2, pulsed dye laser, and Er:YAG), which have proven effective due to their convenient application and fewer complications, the Er:YAG laser stands out for its potential to deliver faster recovery, fewer pigmentation changes, minimal scarring, and a shorter period of postlaser redness. This study evaluated Er:YAG laser for XP in four cases. Three laser sessions effectively treated the lesions, leading to patient satisfaction despite incomplete clearance, with no recurrence in 12 months and no side effects. The study concluded that Er:YAG laser is preferred over other lasers for this condition due to its superior healing profile.

## Linked entities

- **Chemicals:** trichloroacetic acid (PubChem CID 6421), doxorubicin (PubChem CID 31703)

## Full-text entities

- **Diseases:** Periocular Lesion (MESH:D019557)
- **Chemicals:** TCA (MESH:D014238), Er:YAG (-), CO (MESH:D002248)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12170062/full.md

---
Source: https://tomesphere.com/paper/PMC12170062